首页    期刊浏览 2024年11月30日 星期六
登录注册

文章基本信息

  • 标题:Endocrine vasculatures are preferable targets of an antitumor ineffective low dose of anti-VEGF therapy
  • 本地全文:下载
  • 作者:Yin Zhang ; Yunlong Yang ; Kayoko Hosaka
  • 期刊名称:Proceedings of the National Academy of Sciences
  • 印刷版ISSN:0027-8424
  • 电子版ISSN:1091-6490
  • 出版年度:2016
  • 卷号:113
  • 期号:15
  • 页码:4158-4163
  • DOI:10.1073/pnas.1601649113
  • 语种:English
  • 出版社:The National Academy of Sciences of the United States of America
  • 摘要:Anti-VEGF–based antiangiogenic drugs are designed to block tumor angiogenesis for treatment of cancer patients. However, anti-VEGF drugs produce off-tumor target effects on multiple tissues and organs and cause broad adverse effects. Here, we show that vasculatures in endocrine organs were more sensitive to anti-VEGF treatment than tumor vasculatures. In thyroid, adrenal glands, and pancreatic islets, systemic treatment with low doses of an anti-VEGF neutralizing antibody caused marked vascular regression, whereas tumor vessels remained unaffected. Additionally, a low dose of VEGF blockade significantly inhibited the formation of thyroid vascular fenestrae, leaving tumor vascular structures unchanged. Along with vascular structural changes, the low dose of VEGF blockade inhibited vascular perfusion and permeability in thyroid, but not in tumors. Prolonged treatment with the low-dose VEGF blockade caused hypertension and significantly decreased circulating levels of thyroid hormone free-T3 and -T4, leading to functional impairment of thyroid. These findings show that the fenestrated microvasculatures in endocrine organs are more sensitive than tumor vasculatures in response to systemic anti-VEGF drugs. Thus, our data support the notion that clinically nonbeneficial treatments with anti-VEGF drugs could potentially cause adverse effects.
  • 关键词:tumor ; angiogenesis ; VEGF ; antiangiogenic therapy ; adverse effects
国家哲学社会科学文献中心版权所有